Blastocyst transfer after enzymatic treatment of the zona pellucida: improving in-vitro fertilization and understanding implantation.
It has been shown recently that delayed transfers improve implantation rates in assisted reproductive technology programmes. In a prospective study, the pregnancy rates and safety of outcome were evaluated in a group of patients after the transfer of day 5 blastocysts with enzymatic treatment of the zona pellucida. Nineteen women with a mean age of 32.6+/-5.2 years and mean 2.1+/-2.2 repeated attempts had blastocyst transfers with a mean number of 2.5+/-0.7 embryos replaced per patient. The clinical pregnancy rates per cycle/transfer and implantation rate were 53% and 33%, respectively. The multiple pregnancy rate was 40% (two pregnancies were triplets). The pregnancy and implantation rates were very much higher than observed for most assisted reproduction technology centres. The 'in-vitro implantation' rates of zona-free blastocysts on a variety of feeder monolayers was 92%, offering some thoughts as to the role of the zona and interaction of the inner cell mass and trophoectoderm with the endometrium in implantation. Based on the in-vitro studies and the high multiple pregnancy rates, it appears that zona-manipulated blastocysts implant relatively well and there would be a need to reduce the number of transferred embryos to one or two, thus reducing multiple pregnancies and having spare blastocysts available for cryopreservation. The results also suggest that using the embryo culture protocol and method of transfer in the present study offers encouraging improvements to assisted reproduction technology, and enzymatic treatment of the zona may allow better anchorage and dialogue of the embryo with the endometrium, helping us to improve and understand implantation.
Fong
C Y
CY
Department of Obstetrics and Gynaecology, National University Hospital, Kent Ridge, Singapore.
Bongso
A
A
Ng
S C
SC
Kumar
J
J
Trounson
A
A
Ratnam
S
S
D000328:Adult; D001755:Blastocyst / Q000187:drug effects / Q000502:physiology; D010064:Embryo Implantation / Q000187:drug effects* / Q000502:physiology; D004624:Embryo Transfer / Q000009:adverse effects / Q000379:methods*; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D066298:In Vitro Techniques; D007246:Infertility / Q000628:therapy; D008297:Male; D011247:Pregnancy; D018873:Pregnancy Rate; D011272:Pregnancy, Multiple; D011402:Pronase / Q000494:pharmacology*; D011446:Prospective Studies; D012449:Safety; D015044:Zona Pellucida / Q000187:drug effects* / Q000502:physiology
D011402:Pronase